Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Huelgas, Ricardo Gómez; Peralta, Fernando Gómez; Fernández, Lourdes Carrillo; Galve, Enrique; Casanueva, Felipe F.; Puig-Domingo, Manel; Bravo, José Javier Mediavilla; Orozco-Beltrán, Domingo; Muñoz, Javier Ena; Torre, Edelmiro Menéndez; Menéndez, Sara Artola; Ramos, Pilar Mazón; Megías, Susana Monereo; Pedragós, Assumpta Caixàs; Simarro, Flora López; Guisasola, Fernando Álvarez

doi:10.1016/j.rce.2015.07.003

Cited by 15 publications

(11 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recordemos también que el efecto hipoglucemiante de los iSGLT-2 se reduce cuando el filtrado glomerular desciende, aunque, en general, con cifras menores que la que presenta Sebastián (54 mg/gr). Todo ello, hace que la presencia de una ERC aunque leve en este paciente, limite la opción de un iSGLT-2 a canagliflozina y dosis de 100 mg al día sin opción de subir a 300 mg, al menos a día de hoy 7 .…”

Section: Discussionunclassified

“…Por último, el importante objetivo de pérdida de peso se verá apoyado por ambos grupos terapéuticos. El algoritmo de la redGDPS prioriza los arGLP-1 en obesidad Casos clínicos | cuadernos de la redGDPS grado 2 o más por su mayor impacto sobre la pérdida ponderal frente a los iSGLT-2 7,6,8 .…”

Section: Discussionunclassified

“…Además, intentaremos conseguir un peso objetivo y, posteriormente, mantenerlo. Pero todo ello lo llevaríamos a cabo manteniendo el placer de comer y sociabilizar en torno a la comida, adiestrándole sobre la elección de alimentos más conveniente 7 . Nos centraríamos en el conocimiento de la dieta mediterránea, adaptándola a sus preferencias y aplicaríamos una reducción calórica de aproximadamente 500 kcal al día 7,9 .…”

Section: Considerar Factores Específicos Que Afectan a La Elección Del Tratamientounclassified

“…Como ya se ha comentado, la presencia de ERC determina también la elección del hipoglucemiante, porque como ocurre con la ECV, disponemos de fármacos hipoglucemiantes que, además de mejorar el control metabólico, también retrasan la progresión del deterioro de la función renal y de la albuminuria. Se trata de los arGLP-1 4,6 liraglutida, dulaglutida y semaglutida y, entre los iSGLT-2 5,6,7 , canagliflozina, empagliflozina y dapagliflozina.…”

unclassified

See 3 more Smart Citations

Oportunidades para abordar del riesgo cardiometabólico residual del paciente con DM2 en Atención Primaria

Navarro

Miguel²,

Ortega

et al. 2021

Contexto_epidemiologico

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Section: Considerar Factores Específicos Que Afectan a La Elección Del Tratamientounclassified

unclassified

See 2 more Smart Citations

Oportunidades para abordar del riesgo cardiometabólico residual del paciente con DM2 en Atención Primaria

Navarro

Miguel²,

Ortega

et al. 2021

Contexto_epidemiologico

View full text Add to dashboard Cite

show abstract

“…T2DM is a complex disease with a progressive course. Obesity, linked to insulin resistance, is the basis where relative insulin deficiency and other physiopathological alterations promote the development of metabolic and cardiovascular (CV) alterations 4. It is also the most challenging problem to manage in clinical practice, significantly conditioning therapeutic adherence.…”

Section: Introductionmentioning

confidence: 99%

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

Gómez-Peralta¹,

Abreu²

2019

DDDT

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.

show abstract

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucoselowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with established cardiovascular disease (CVD), regardless of glycaemic control, with lifestyle modification and metformin. However, several studies have recently highlighted the limited number of patients with T2D benefiting from these medications worldwide. Given the huge burden of CVD among patients with T2D, efforts should be made to bring clinical practice closer to expert guidelines. This review describes the current situation of GLP-1 RA use in Spain and the reasons behind the gap between guidelines and realworld practice and suggests possible solutions.

show abstract

Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Cited by 15 publications

References 86 publications

Oportunidades para abordar del riesgo cardiometabólico residual del paciente con DM2 en Atención Primaria

Oportunidades para abordar del riesgo cardiometabólico residual del paciente con DM2 en Atención Primaria

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Contact Info

Product

Resources

About